Unknown PHASE3 INTERVENTIONAL 2-arm NCT03601975

Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma

Phase III Randomized Trial of Anlotinib Plus Gemcitabine/Cisplatin Vesus Placebo Plus Gemcitabine/Cisplatin in Previous Untreated Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions Nasopharyngeal Carcinoma

Interventions Gemcitabine/Cisplatin

Updated 8 times since 2018 Last updated: Feb 1, 2019 Started: Aug 27, 2018 Primary completion: Jul 30, 2020 Completion: Jul 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Nasopharyngeal Carcinoma, this trial is ongoing. The trial is conducted by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and has accumulated 8 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE3
Mar 2019 — Jan 2021 [monthly]

Recruiting PHASE3

▶ Show 3 earlier versions

Jan 2019 — Mar 2019 [monthly]

Recruiting PHASE3
Oct 2018 — Jan 2019 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Aug 2018 — Oct 2018 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Data source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China